Sunlenca Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Lenacapavir

Indications/Uses

In combination w/ other antiretroviral(s) for adults w/ multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. FC tab: Oral loading prior to administration of long-acting lenacapavir inj.

Dosage/Direction for Use

Initiation 600 mg FC tab on days 1 & 2, 300 mg FC tab on day 8, 927 mg SC inj on day 15. Maintenance 927 mg SC inj every 6 mth from the date of last inj.

Administration

FC tab: May be taken with or without food. Do not chew/crush/split.

Contraindications

Hypersensitivity. Co-administration w/ strong CYP3A, P-gp, & UGT1A1 inducers eg, antimycobacterials (rifampicin), anticonvulsants (carbamazepine, phenytoin), herbal products (St. John's wort).

MIMS Class

Antivirals

ATC Classification

J05AX31 - lenacapavir ; Belongs to the class of other antivirals. Used as a direct acting antiviral in the systemic treatment of viral infections.

Regulatory Classification

POM

Presentation/Packing

Form

Sunlenca film-coated tab 300 mg

Packing/Price

1's

Form

Sunlenca soln for inj 463.5 mg/1.5 mL

Packing/Price

1's

Sunlenca

Manufacturer:

Gilead Sciences